Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (. 2021 Sep 30;13:17588359211049639)
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-04-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359231168509 |
| _version_ | 1797844724998995968 |
|---|---|
| author | Hidekatsu Nakai Noriomi Matsumura |
| author_facet | Hidekatsu Nakai Noriomi Matsumura |
| author_sort | Hidekatsu Nakai |
| collection | DOAJ |
| first_indexed | 2024-04-09T17:27:38Z |
| format | Article |
| id | doaj.art-eec7ae4828aa47ca82bbbdfd04d48e3e |
| institution | Directory Open Access Journal |
| issn | 1758-8359 |
| language | English |
| last_indexed | 2024-04-09T17:27:38Z |
| publishDate | 2023-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj.art-eec7ae4828aa47ca82bbbdfd04d48e3e2023-04-18T11:04:47ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592023-04-011510.1177/17588359231168509Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (. 2021 Sep 30;13:17588359211049639)Hidekatsu NakaiNoriomi Matsumurahttps://doi.org/10.1177/17588359231168509 |
| spellingShingle | Hidekatsu Nakai Noriomi Matsumura Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (. 2021 Sep 30;13:17588359211049639) Therapeutic Advances in Medical Oncology |
| title | Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (. 2021 Sep 30;13:17588359211049639) |
| title_full | Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (. 2021 Sep 30;13:17588359211049639) |
| title_fullStr | Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (. 2021 Sep 30;13:17588359211049639) |
| title_full_unstemmed | Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (. 2021 Sep 30;13:17588359211049639) |
| title_short | Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (. 2021 Sep 30;13:17588359211049639) |
| title_sort | comment on population adjusted indirect treatment comparison of maintenance parp inhibitor with or without bevacizumab bevacizumab alone in women with newly diagnosed advanced ovarian cancer 2021 sep 30 13 17588359211049639 |
| url | https://doi.org/10.1177/17588359231168509 |
| work_keys_str_mv | AT hidekatsunakai commentonpopulationadjustedindirecttreatmentcomparisonofmaintenanceparpinhibitorwithorwithoutbevacizumabbevacizumabaloneinwomenwithnewlydiagnosedadvancedovariancancer2021sep301317588359211049639 AT noriomimatsumura commentonpopulationadjustedindirecttreatmentcomparisonofmaintenanceparpinhibitorwithorwithoutbevacizumabbevacizumabaloneinwomenwithnewlydiagnosedadvancedovariancancer2021sep301317588359211049639 |